Literature DB >> 19833394

Managing non-paraneoplastic Lambert-Eaton myasthenic syndrome: clinical characteristics in 25 German patients.

Hannah L Pellkofer1, Lena Armbruster, Rainer Linke, Friedrich Schumm, Raymond Voltz.   

Abstract

In about 40% of patients LEMS is not a paraneoplastic phenomenon (NT-LEMS). Several clinical aspects important to these patients remain open, especially the question when a LEMS can definitely be diagnosed as NT-LEMS. Here we describe a series of 25 German NT-LEMS patients regarding their clinical characteristics, duration of symptoms, value of serological markers, paraneoplastic antibodies and FDG-PET/CT. Furthermore, we discuss the current diagnostic criteria of NT-LEMS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19833394     DOI: 10.1016/j.jneuroim.2009.09.017

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  5 in total

1.  Lambert-Eaton Myasthenic Syndrome with A Twenty-Three-Year Delay in Diagnosis.

Authors:  Elif Gökçal; Azize Esra Gürsoy; Talip Asil; Mustafa Ertaş
Journal:  Noro Psikiyatr Ars       Date:  2017-01-19       Impact factor: 1.339

Review 2.  Voltage gated calcium channel antibody-related neurological diseases.

Authors:  Can Ebru Bekircan-Kurt; Eda Derle Çiftçi; Aslı Tuncer Kurne; Banu Anlar
Journal:  World J Clin Cases       Date:  2015-03-16       Impact factor: 1.337

3.  Lambert-eaton myasthenic syndrome; pathogenesis, diagnosis, and therapy.

Authors:  Nils Erik Gilhus
Journal:  Autoimmune Dis       Date:  2011-09-29

Review 4.  The association between Lambert-Eaton myasthenic syndrome and small cell lung carcinoma.

Authors:  Sarah Ew Briggs; Paul Gozzard; Denis C Talbot
Journal:  Immunotargets Ther       Date:  2013-05-21

Review 5.  Paraneoplastic ocular syndrome: a pandora's box of underlying malignancies.

Authors:  Prathama Sarkar; Amit Mehtani; Harish Chandar Gandhi; Jatinder Singh Bhalla; Satish Tapariya
Journal:  Eye (Lond)       Date:  2021-08-03       Impact factor: 4.456

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.